PROactively TACkling CDK4/6 therapy resistance
- PMID: 35121999
- DOI: 10.1038/s43018-021-00193-w
PROactively TACkling CDK4/6 therapy resistance
Comment on
-
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.Nat Cancer. 2021 Apr;2(4):429-443. doi: 10.1038/s43018-021-00174-z. Epub 2021 Mar 1. Nat Cancer. 2021. PMID: 34568836 Free PMC article.
References
-
- Subbiah, V., Baik, C. & Kirkwood, J. M. Trends Cancer 6, 797–810 (2020). - DOI
-
- Goel, S., DeCristo, M. J., McAllister, S. S. & Zhao, J. J. Trends Cell Biol. 28, 911–925 (2018). - DOI
-
- Wu, X. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00174-z (2021). - DOI - PubMed
-
- Teh, J. L. F. & Aplin, A. E. Clin. Cancer Res. 25, 921–927 (2019). - DOI
-
- AbuHammad, S. et al. Proc. Natl Acad. Sci. USA 116, 17990–18000 (2019). - DOI